SCHEMBL21376784

SCHEMBL21376784

COc1ccc(N(C)Sc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.61
▸ CA2 P00918 2/20 0.61
▸ NPC1 O15118 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ XDH P47989 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ CES2 O00748 2/20 0.44
▸ CES1 P23141 2/20 0.44
▸ CHEK1 O14757 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ RXRA P19793 1/20 0.44
▸ TAS2R14 Q9NYV8 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ FFAR1 O14842 1/20 0.43
▸ PLA2G4B P0C869 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21909789 0.83 HSD17B2 (0.50) CA1CA2NPC1RAB9AKDM4E
SCHEMBL21376794 0.83 BCL2L1 (0.52) NPC1POLBRAB9ASMN1; SMN2KDM4E
SCHEMBL21376318 0.82 TSHR (0.45) NPC1POLBRAB9ASMN1; SMN2CES2
SCHEMBL21376506 0.81 TSHR (0.55) NPC1POLBSMN1; SMN2KDM4EHPGD
SCHEMBL21376519 0.80 NR4A2 (0.65) NPC1POLBRAB9ASMN1; SMN2RXRA
SCHEMBL17527110 0.79 CA1 (0.77) CA1CA2NPC1POLBRAB9A
SCHEMBL6932815 0.79 CA1 (0.77) CA1CA2NPC1POLBRAB9A
P-Anisic Acid SCHEMBL1157044 0.78 CA1 (1.00) CA1CA2NPC1POLBRAB9A
P-Anisic Acid SCHEMBL43335 0.78 CA1 (1.00) CA1CA2NPC1POLBRAB9A
SCHEMBL21376314 0.78 SRD5A2 (0.54) NPC1POLBRAB9ACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3626240-A1 PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP StemSynergy Therapeutics, Inc. (US) 2020-03-25 — — EP disclosed
EP-2403499-B1 METHODS AND COMPOSITIONS FOR USE IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS INC (US) 2019-09-18 — — EP disclosed
Send feedback